The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial
Open accessAbstract
Importance: Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic colorectal cancer, but the optimal choice of the initial biologic therapy in previously untreated patients is unknown. Objective: To determine if the addition of cetuximab vs bevacizumab to the combination of leucovorin, fluorouracil, and oxaliplatin (mFOLFOX6) regimen or the combination of leucovorin, fluorouracil, and irinotecan (FOLFIRI) regimen is superior as first-line therapy in advanced or metastatic KRAS wild-type (wt) colorectal cancer. Design, Setting, and Participants: Patients (≥18 years) enrolled at community and academic centers throughout the National Clinical Trials Network in the United States and Canada (November 2005-March 2012) with previously untreated advanced or metastatic colorectal cancer whose tumors were KRAS wt chose to take either the mFOLFOX6 regimen or the FOLFIRI regimen as chemotherapy and were randomized to receive either cetuximab (n = 578) or bevacizumab (n = 559). The last date of follow-up was December 15, 2015. Interventions: Cetuximab vs bevacizumab combined with either mFOLFOX6 or FOLFIRI chemotherapy regimen chosen by the treating physician and patient. Main Outcomes and Measures: The primary end point was overall survival. Secondary objectives included progression-free survival and overall response rate, site-reported confirmed or unconfirmed complete or partial response. Results: Among 1137 patients (median age, 59 years; 440 [39%] women), 1074 (94%) of patients met eligibility criteria. As of December 15, 2015, median follow-up for 263 surviving patients was 47.4 months (range, 0-110.7 months), and 82% of patients (938 of 1137) experienced disease progression. The median overall survival was 30.0 months in the cetuximab-chemotherapy group and 29.0 months in the bevacizumab-chemotherapy group with a stratified hazard ratio (HR) of 0.88 (95% CI, 0.77-1.01; P = .08). The median progression-free survival was 10.5 months in the cetuximab-chemotherapy group and 10.6 months in the bevacizumab-chemotherapy group with a stratified HR of 0.95 (95% CI, 0.84-1.08; P = .45). Response rates were not significantly different, 59.6% vs 55.2% for cetuximab and bevacizumab, respectively (difference, 4.4%, 95% CI, 1.0%-9.0%, P = .13). Conclusions and Relevance: Among patients with KRAS wt untreated advanced or metastatic colorectal cancer, there was no significant difference in overall survival between the addition of cetuximab vs bevacizumab to chemotherapy as initial biologic treatment. Trial Registration: clinicaltrials.gov identifier: NCT00265850.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Also, patients with metastatic colorectal cancer and related intestinal malignancies tend to receive similar treatments and live for many months with relatively stable health (median overall survival >2 years) [44], facilitating study completion and potentially derivation of durable benefit from the intervention.”
From Being present: A single-arm feasibility study of audio-based mindfulness meditation for colorectal cancer patients and caregivers (2018) · cites this paper as [44]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although a higher percentage of men enrolled compared to most prior mindfulness interventions for integrative cancer care [34], the evaluable study sample included a greater proportion of younger (age <50), female, White and Latino or Hispanic patients relative to the underlying population [44, 53].”
From Being present: A single-arm feasibility study of audio-based mindfulness meditation for colorectal cancer patients and caregivers (2018) · cites this paper as [44]
Experimental — accuracy not yet measuredIn the citing paper
“This trial demonstrated that patients in the cetuximab plus chemotherapy group had slightly higher overall survival versus patients in the bevacizumab plus chemotherapy group (30.0 months versus 29.0 months).”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [65]
In the citing paper
“Similar to the FIRE-3 trial, median progression-free survival and response rates were similar between groups.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [65]
In the citing paper
“Similarly, the CALGB/SWOG 80405 trial showed that both cetuximab and bevacizumab provided comparable outcomes when combined with chemotherapy in the overall population, but the benefit of anti-EGFR therapy was again limited to RAS wild-type tumors [21].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [21]
In the citing paper
“however, it must be noted here that this pooled analysis also included patients who had received a nonstandard treatment regimen, including FUFIRI, FUFOX, and mIROX as induction chemotherapies and bevacizumab monotherapy or observation alone as maintenance therapies in clinical trials [22,23].”
From The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study (2021) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 2×
“dence indicated that cetuximab activity was unrelated to tumor expression of EGFR.(8) Bevacizumab, a humanized”
BackgroundThe consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815 · cited 1×
“a The 0-to-5 coded scale describing patient daily level of functioning from fully active (0) to completely disabled (4); dead (5).”
BackgroundDouillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256 · cited 4×
“Results are reported for (1) the primary 2-group comparison between cetuximab and bevacizumab; (2) the comparison of cetuximab vs bevacizumab in an expanded RAS subset described above; and (3) the chemotherapy subgroups.”
MethodInfluentialSaltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740
Flagged first, then by citations
Cited by
Sorted by citations
Items 701–800 of 900
Kawazoe, T., Nakanishi, R., Ando, K., Zaitsu, Y., Kudou, K., Nakanoko, T., Itoh, S., Oki, E., & Yoshizumi, T. (2025) · Surgery Today · doi:10.1007/s00595-025-03125-8 · Cited by 1
Yamamoto, K., Bando, H., Misumi, T., Nishikawa, T., Wakabayashi, M., Yamazaki, K., Maehara, Y., Oki, E., Saltz, L. B., Douillard, J.-Y., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.116034 · Cited by 1
Self-citationTreatment options for advanced small bowel adenocarcinoma: a systematic review
Ghidini, M., Parisi, A., Zurlo, I. V., Laterza, M. M., Gervaso, L., Ricci, A. D., Biasi, A., Nicastro, A., Garrone, O., Tomasello, G., et al. (2025) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2025.100248 · Cited by 1
Positioning EGFR re-treatment in modern metastatic colorectal cancer: insights from PARERE
Cann, C., & Eng, C. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.10.008 · Cited by 1
Kudura, K., Ritz, N., Schaulin, Y., Miszczyszyn, A., Kutzker, T., Engel, R., Torney, M. V. S. U., Harms, W., & Foerster, R. (2025) · Cancers · doi:10.3390/cancers17213592 · Cited by 1
Ashouri, K., Millstein, J., Yang, Y., Xiu, J., Soni, S., Mittal, P., Algaze, S., Torres-Gonzalez, L., Jayachandran, P., Zhang, W., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013186 · Cited by 1
Self-citationFang, Z., Zhan, S., Mao, C., Zhang, N., Zhao, X., Huang, Y., Ding, W., & Ma, Z. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118573 · Cited by 1
Pu, T., Peddle, A. M., Wirapati, P., Tsantoulis, P. K., Wu, Q., Hong, Y., Samuel, L. M., Desai, J., Riener, M., Saridaki, Z., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-025-01253-5 · Cited by 1
Cashin, P., Morris, D. L., Esquivel, J., Larsen, S. G., Takala, H., Dumont, F., Sourrouille, I., Képénékian, V., Tuech, J., Béréder, J.-M., et al. (2026) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2026.111437 · Cited by 1
Li, Y.-N., Deng, F.-W., Lan, T.-Q., Lu, Y., Xiang, L., Song, G.-B., Peng, T., Cheng, X., & Ying, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1683928 · Cited by 1
Wu, Z., Li, X., Xiao, C., You, F., & Su, L. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.121292 · Cited by 2
Can, S., Çakıcı, V., Kahveci, G. B., Eroğlu, Ş., Tok, B., UYGUN, G., Özer, E., Cirak, Y., & Gökmen, İ. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15072805 · Cited by 1
“…data demonstrating the superiority of bevacizumab-containing combinations over cetuximab-based regimens in patients with peritoneal metastasis—with longer progression-free survival (9.6 vs. 6.1 months) and overall survival (26.3 vs. 12.7 months)—lend further support to this approach [21].”
InfluentialChibaudel, B., Dourthe, L.-M., André, T., Henriques, J., Bourgeois, V., Etienne, P.-L., Desrame, J., Carola, É., Dupuis, O., Baba-Hamed, N., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02639-y · Cited by 1
Álvarez, G., Capdevila, J., García‐Carbonero, R., Jimenez-Fonseca, P., Benavent, M., Vicente, M. Á., Llanos, M., López, C., Alonso, V., García-Centeno, R., et al. (2026) · Neuroendocrinology · doi:10.1159/000552234 · Cited by 1
Compte-rendu du congrès de l’ASCO 2016
Aparicio, T., Lièvre, A., & Bibeau, F. (2016) · Côlon & Rectum · doi:10.1007/s11725-016-0670-2 · Cited by 1
Shibutani, M., Maeda, K., Nagahara, H., Fukuoka, T., Iseki, Y., Matsutani, S., Wang, E., Hirakawa, K., & Ohira, M. (2018) · Case Reports in Oncology · doi:10.1159/000490698 · Cited by 1
Matsuhashi, N., Tomita, H., Tanaka, H., Iwata, Y., Matsui, S., Imai, H., Fukada, M., Mizutani, C., Takahashi, T., Yasufuku, I., et al. (2022) · Molecular and Clinical Oncology · doi:10.3892/mco.2022.2494 · Cited by 1
“In the PEAK (18), FIRE‐3 (19) and CALGB/SWOG 80405 (20) randomized controlled trials performed to compare beva‐ cizumab and anti‐EGFR therapy for the progression of recurrent CRC, anti‐EGFR was also confirmed to have a positive effect on survival extension in the presence of wild‐type RAS.”
BackgroundMartins, D. F., Rodrigues, J. R., Redondo, P., Julião, I., & Faustino, C. (2022) · Cureus · doi:10.7759/cureus.23543 · Cited by 1
“This study is of particular interest since data regarding the best treatment sequence with these therapies is lacking and, also because, most studies that compared bevacizumab and EGFRi in first-line setting did not account for the impact of subsequent therapies [3,8].”
BackgroundResultInfluentialPalmieri, L., Büchler, T., Meyer, A., Veškrňová, V., Fiala, O., Brabec, P., Baranová, J., & Coriat, R. (2022) · Cancers · doi:10.3390/cancers14061410 · Cited by 1
Current Updates on HER2–Directed Therapies in Metastatic Colorectal Cancer
Fencer, M. G., Davis, C. H., & Spencer, K. R. (2022) · Current Colorectal Cancer Reports · doi:10.1007/s11888-022-00475-0 · Cited by 1
Li, W., Zhou, J. H., Zhang, T., Tai, Y., Xu, Y., Bai, Y., Jiang, Y., Lu, Z., Li, L., Huang, J., et al. (2022) · PubMed Central · Cited by 1
Gathirua‐Mwangi, W. G., Yang, T. T., Khan, T., Wu, Y., & Afable, M. G. (2022) · Future Oncology · doi:10.2217/fon-2022-0432 · Cited by 1
Bekaii‐Saab, T., Balser, S., Lohmann, R., Daoud, H., Liedert, B., & Schliephake, D. E. (2022) · Colorectal Cancer · doi:10.2217/crc-2022-0002 · Cited by 1
Trouiller, J.-B., Macabeo, B., Poll, A., Howard, D., Buckland, A., Sivignon, M., Clay, E., Malka, D., Samalin, E., Toumi, M., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-063700 · Cited by 1
Lara-Morga, C., Palka-Kotlowska, M., Custodio‐Cabello, S., Pacheco-Barcía, V., & Cabezón‐Gutiérrez, L. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00136 · Cited by 1
“Patients with KRAS/neuroblastoma rat sarcoma viral oncogene homolog (NRAS)/BRAF wild-type metastatic CRC, median survival with treatment is approximately 30 months, with survival rates of 80% at 1 year, 40% at 3 years and 20% at 5 years after the start of first-line chemotherapy [8].”
BackgroundDeng, J., Zeng, X., Hu, W., Yue, T., Luo, Z., Zeng, L., Li, P., & Jiang, C. (2023) · International Journal of Colorectal Disease · doi:10.1007/s00384-023-04442-5 · Cited by 1
Zurloh, M., Goetz, M., Herold, T., Treckmann, J. W., Markus, P. M., Schumacher, B. M., Albers, D., Rink, A., Rosery, V., Zaun, G., et al. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05141-y · Cited by 1
“Mutations of the KRAS or NRAS oncogene are detected in up to 55% of all mCRCs and are strong negative predictors for the efficacy of monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) (Stintzing et al. 2017; Venook et al. 2017).”
BackgroundJiang, D., Parshad, S., Zhan, L. J., Sim, H., Siu, L. L., Liu, G., Shapiro, J. D., Price, T. J., Jonker, D. J., Karapetis, C. S., et al. (2023) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2023.08.006 · Cited by 1
Shin, J. E., An, H. J., Shim, B. Y., Kim, H., Park, H. S., Cho, H., Kye, B., Yoo, R. N., Moon, J.-Y., Kim, S. H., et al. (2023) · Cancers · doi:10.3390/cancers15205057 · Cited by 1
“Over the past 20 years, advances in systemic treatments, including biologically targeted agents, have led to dramatic improvements in the overall survival (OS) of patients with stage IV CRC, exceeding 30 months [1].”
BackgroundMullin, G., Sternschuss, M., Landman, Y., Sulkes, A., & Brenner, B. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i11.1913 · Cited by 1
q-Diffusion leverages the full dimensionality of gene coexpression in single-cell transcriptomics
Marmarelis, M. G., Littman, R., Battaglin, F., Niedzwiecki, D., Venook, A. P., Ambite, J. L., Galstyan, A., Lenz, H., & Steeg, G. V. (2024) · Communications Biology · doi:10.1038/s42003-024-06104-w · Cited by 1
Self-citationPham, H., Ramanujam, S., Yeoh, H., Antippa, P. N., Houli, N., Thomson, B., Kosmider, S., Dunn, C., To, Y. H., Lee, M., et al. (2024) · Surgical Oncology Insight · doi:10.1016/j.soi.2024.100076 · Cited by 1
Guler, O., Hurmuz, P., Atalar, B., Guney, Y., Sağlam, E., Akyurek, S., Bolukbasi, Y., Gural, Z., Tuğrul, F., Korcum, A., et al. (2024) · Strahlentherapie und Onkologie (Print) · doi:10.1007/s00066-024-02291-x · Cited by 1
Chen, Y., Chang, T., Su, W., Yeh, Y., Chen, P.-J., Huang, P.-J., Yang, P.-H., Tsai, H., Wang, J., & Huang, C. (2024) · International Journal of Colorectal Disease · doi:10.1007/s00384-024-04745-1 · Cited by 1
Chen, J., Yu, W., Xia, X., Zhao, Y., Tang, Q., Zhang, Y., Zhang, Y., Zhang, H., Zhang, Z., Zhang, X., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1570457 · Cited by 1
Systemic chemotherapy for colorectal cancer: a narrative review
Hwang, J. (2025) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0123 · Cited by 1
Kim, C., Ahmed, S., Ahmed, S., Brunet, B., Chalchal, H. I., Deobald, R. G., Döll, C., Dupre, M. P., Gordon, V., Lee‐Ying, R. M., et al. (2018) · Current Oncology · doi:10.3747/co.25.4109 · Cited by 1
Yeatman, T. J., Yang, M., & Coppola, D. (2018) · Case Reports in Gastroenterology · doi:10.1159/000494751 · Cited by 1
Therapie mit monoklonalen Antikörpern in der Gastroenterologie
Dobsch, P., Michels, B., Müller-Schilling, M., & Kandulski, A. (2019) · Der Internist · doi:10.1007/s00108-019-00682-2 · Cited by 1
Onkologische Therapiekonzepte bei systemischer Metastasierung des kolorektalen Karzinoms
Modest, D. P., & von Bergwelt‐Baildon, M. (2019) · Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie · doi:10.1055/a-0895-6007 · Cited by 1
“[45] Venook AP, Niedzwiecki D, Lenz HJ et al.”
BackgroundUrgent issues of drug therapy and possible solutions
Карабина, Е. В. (2020) · Practical oncology · doi:10.31917/2102106 · Cited by 2
Znaczenie kliniczne umiejscowienia ogniska pierwotnego raka jelita grubego
Janiak, A., Połowinczak-Przybyłek, J., Czyżykowski, R. Ł., & Potemski, P. (2021) · Oncology in Clinical Practice · doi:10.5603/ocp.2020.0043 · Cited by 1
“In the US CALGB/SWOG 80405 trial, which included 1137 KRAS wild-type patients, the cetuximab + FOLFIRI/FOLFOX was compared to bevacizumab + FOLFIRI/FOLFOX [25].”
MethodPolite, B. N. (2019) · Springer eBooks · doi:10.1007/978-3-030-31471-2_7 · Cited by 1
Self-citationPredicting the benefit of stereotactic body radiotherapy of colorectal cancer metastases
Lindberg, S., Onjukka, E., Wersäll, P. J., Staff, C., Lewensohn, R., Masucci, G. V., & Lindberg, K. (2022) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2022.07.006 · Cited by 1
“Palliative chemotherapy is associated with a median overall survival (OS) of 30 months [2,7] and a 5-year OS-rate of 14 % [1] and is the main oncological treatment for mCRC.”
BackgroundTo Take or Not to Take a Side: That Is the Question
Parikh, D. A., & Lin, A. Y. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01767 · Cited by 1
Huh, H. (2019) · UWSpace (University of Waterloo) · Cited by 1
Are We Finally Moving toward Personalized Therapy in Colorectal Cancer?
Gill, S. (2019) · Current Oncology · doi:10.3747/co.26.5943 · Cited by 1
Genes and Race in Colon Cancer
Stebbing, J., & Schlechter, B. L. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.02094 · Cited by 1
Smabers, L. P., Wensink, G. E., Veríssimo, C. S., Koedoot, E., Pitsa, K.-C., Huismans, M. A., Barón, C. H., Doorn, M., Iersel, L. V., Cirkel, G. A., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3794312/v1 · Cited by 1
Compte-rendu du congrès de l’ASCO 2017
Aparicio, T. (2017) · Côlon & Rectum · doi:10.1007/s11725-017-0734-y
Stellenwert der systemischen Chemotherapie bei fortgeschrittener peritonealer Metastasierung
Golombek, T., & Lordick, F. (2018) · Springer eBooks · doi:10.1007/978-3-662-54500-3_26
Oligometastasierung beim kolorektalen Karzinom – moderne Therapiekonzepte
Binnebösel, M., Lambertz, A., Dejong, K., & Neumann, U. P. (2018) · Der Chirurg · doi:10.1007/s00104-018-0661-y
Bibeau, F., Bouard, G., & Pho, D. (2018) · Côlon & Rectum · doi:10.3166/cer-2018-0032 · Cited by 1
What Is the Best Systemic Therapy for Left-sided RAS Wild-type Metastatic Colorectal Cancer?
Lee, J. J. (2018) · Current Colorectal Cancer Reports · doi:10.1007/s11888-018-0414-9
Second-Line Chemotherapy in Colorectal Cancer
Sugimoto, N. (2018) · Nihon Daicho Komonbyo Gakkai Zasshi · doi:10.3862/jcoloproctology.71.380
Recent Progress in First-Line Chemotherapy in Metastatic Colorectal Cancer
Shimada, Y. (2018) · Nihon Daicho Komonbyo Gakkai Zasshi · doi:10.3862/jcoloproctology.71.371
TAILORing targeted therapies to the right patient at the right time: how close are we?
Zarkavelis, G., & Pentheroudakis, G. E. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.10.75
“7 months in the combination therapy arm, in sharp contrast to median OS of 33 months reported in FIRE 3 and 32 months reported in GALGB/SWOG 80405 (the latter mostly using FOLFOX regimens) (9,13).”
ResultOligometastasierung beim kolorektalen Karzinom – moderne Therapiekonzepte
Binnebösel, M., Lambertz, A., Dejong, K., & Neumann, U. P. (2018) · coloproctology · doi:10.1007/s00053-018-0312-2
Soveri, L. (2019) · Työväentutkimus Vuosikirja
Ursem, C. J., & Venook, A. P. (2017) · PubMed
Self-citationPostoperative Oncologic Management of Colorectal Cancer Emergencies
Kempf, E., Baumgaertner, I., & Tournigand, C. (2019) · Hot topics in acute care surgery and trauma · doi:10.1007/978-3-030-06225-5_21
MSI und Tumormutationslast beim kolorektalen Karzinom
Kütting, F., Bludau, M., Alakus, H., & Bruns, C. J. (2019) · Der Onkologe · doi:10.1007/s00761-019-0611-4
“Die Studie, die 1137 Patienten mit KRASWildtyp(WT)-CRC (Kodon 12+ 13) einschließen konnte, zeigte keinen statistischen Unterschied zwischen den beiden verbliebenen Armen bezüglich des primären Endpunkts Gesamtüberleben (OS; [1]).”
BackgroundDiagnostik und Therapie des kolorektalen Karzinoms
Wilhelm, D., Klare, P., Nennstiel, S., Dapper, H., Combs, S. E., Liotta, L., & Quante, M. (2019) · Der Klinikarzt · doi:10.1055/a-0957-2659
Stintzing, S., & Heinemann, V. (2019) · Forum · doi:10.1007/s12312-019-0653-y
Sequencing of Systemic Chemotherapy for Unresectable CRLM
Roth, M. T., & Goff, L. W. (2019) · Springer eBooks · doi:10.1007/978-3-030-25486-5_23
The efficacy of panitumumab in refractory metastatic colorectal cancer: A meta-analysis.
Duan, K., & Wang, H. (2019) · PubMed
Therapiesequenz beim metastasierten kolorektalen Karzinom
von Einem, J. C., & Stintzing, S. (2020) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-020-8020-9
“Da sowohl der VEGFAntiköper Bevaci zumab als auch die beiden AntiEGFRAntikörper Cetuximab und Panitumumab zugelassen sind, wurden die Ergebnisse der vergleichenden Studien CALGB/SWOG 80405, FIRE3 (AIO KRK0306) und PEAK intensiv diskutiert [10, 11, 12].”
BackgroundPiccirillo, M. C., Avallone, A., Carlomagno, C., Maiello, E., Rosati, G., Alabiso, O., Nasti, G., Placido, S. D., Latiano, T., Bilancia, D., et al. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.05.009
Chemotherapy and Targeted Drugs for Patients with Metastatic Colorectal Cancer
Pfeiffer, P., & Qvortrup, C. (2020) · Springer eBooks · doi:10.1007/978-3-030-58846-5_21
Systemische Therapie des metastasierten Kolonkarzinoms
Kurreck, A., Modest, D. P., von Einem, J., & Stintzing, S. (2020) · Der Onkologe · doi:10.1007/s00761-020-00875-7
[Global research hotspots on oncology-bibliometric analysis based on the ESI hot papers].
Han, X., Li, X., Gong, X., Li, B., Bai, B., Zhang, L., Pu, J. Y., Li, Y., & Zhang, M. (2020) · PubMed · doi:10.7507/1001-5515.202009083
Chang, H. L., & Jones, A. L. (2021) · Current Colorectal Cancer Reports · doi:10.1007/s11888-021-00464-9
Foroughi, S., Hutchinson, R. A., Wong, H., Christie, M., Batrouney, A., Wong, R., Lee, M., Tie, J., Burgess, A. W., & Gibbs, P. (2020) · Growth Factors · doi:10.1080/08977194.2021.1878166
Importance of Systemic Chemotherapy in Advanced Peritoneal Metastasis
Golombek, T., Brandl, A., & Lordick, F. (2021) · Springer eBooks · doi:10.1007/978-3-030-62640-2_26
Juzėnas, S., Lukoševičius, R., Šaltenienė, V., Kulokiene, U., Hemmrich‐Stanisak, G., Franke, A., Link, A., Ruzgys, P., Šatkauskas, S., Paužas, H., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-558860/v1
Targeted agents in older patients with gastrointestinal cancers – An overview
Monteiro, A. R., Saúde-Conde, R., Basto, R., Sclafani, F., Deleporte, A., Hendlisz, A., & Lago, L. D. (2021) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2021.06.013
Refractory metastatic colorectal cancer: challenges and solutions during the COVID-19 pandemic
Sekacheva, M. I., Fatyanova, A. S., Meretukov, D. A., Zhilenkova, A. V., Rusanov, A. S., Rozhkov, A., Guryanova, A., & Bagmet, N. N. (2021) · Journal of Modern Oncology · doi:10.26442/18151434.2021.2.200904
祐太郎, 久. (2021) · Institutional Repositories DataBase (IRDB) · doi:10.14930/jshowaunivsoc.81.139
A roadmap for medical treatment of metastatic CRC
Martínez-Bernal, G., Martínez‐Pérez, J., & Valladares‐Ayerbes, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90055-3.00016-8
Therapiestrategien beim synchron metastasierten Kolonkarzinom
Rasbach, E., Birgin, E., Betzler, A. M., Rahbari, N. N., & Reißfelder, C. (2022) · coloproctology · doi:10.1007/s00053-022-00601-4
Demir, L., & ERSOY, M. (2022) · OSMANGAZİ JOURNAL OF MEDICINE · doi:10.20515/otd.986616
Medicina de precisión en cáncer colorrectal y gastroesofágico avanzado
Reyes, J. M. (2022) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2022.03.003
(2020) · PeerJ · doi:10.7287/peerj.9149v0.1/reviews/1
“Left colon cancer was found to be more sensitive to anti-EGFR targeted therapy than right colon cancer (Venook et al., 2017).”
BackgroundDe, S. K. (2022) · Wiley eBooks · doi:10.1002/9783527838561.ch7
Ovarian, Vaginal, and Vulvar Cancer
De, S. K. (2022) · Wiley eBooks · doi:10.1002/9783527838561.ch14
Panitumumab beats bevacizumab in RAS wildtype left-sided metastatic colorectal cancer
Yoshino, T., & van den Heuvel, R. (2022) · doi:10.55788/36e81ef6
Clinical Application of Circulating Tumor DNA Analysis
Won, D., Heo, J., Kim, H., Shin, S., & Lee, S. (2022) · Laboratory Medicine Online · doi:10.47429/lmo.2022.12.4.235
Albornoz, A., Luca, R., Mendez, G. A., Moreno, M., Esteso, F., Bruno, L. I., Chacón, M., & O’Connor, J. M. (2022) · Oncología Clínica · doi:10.56969/oc.v26i1.8
Downsizing Chemotherapy for Liver Metastases from Colorectal Cancer
Adam, R. A., & Lévi, F. (2022) · Springer eBooks · doi:10.1007/978-3-031-09323-4_24
Treatment Refractory Metastatic Colorectal Cancer
Huey, R. W., & Raghav, K. P. S. (2022) · Springer eBooks · doi:10.1007/978-3-031-09323-4_32
Riediger, C., Kühn, J., Krause, M., Lohaus, F., & Folprecht, G. (2023) · Die Onkologie · doi:10.1007/s00761-023-01302-3
“Patienten mit einem linksseitigen Primärtumor und einem RAS/BRAF-Wildtyp haben mit einer anti-EGFR-haltigen ChemotherapieKombination (FOLFOX oder FOLFIRI) Ansprechraten von ca 70% [13, 38].”
BackgroundTreatment of KRAS Mutant Microsatellite Stabilized Advanced Colorectal Cancer
朱, 增. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1351137
Yamazaki, K., Yuki, S., Oki, E., Sano, F., Makishima, M., Aoki, K., Hamano, T., & Yamamoto, K. (2023) · Future Oncology · doi:10.2217/fon-2022-1284
Zou, J. P., Zhong, J.-Y., Zou, R., Huang, D., Liu, Y., Liu, Y., Gong, W.-J., Li, X.-W., Tao, J., & Yang, X.-L. (2023) · Research Square · doi:10.21203/rs.3.rs-3301383/v1
Protásio, B. M., Castria, T. B. D., Natalino, R. J. M., Mangone, F. R., Saragiotto, D. F., Sabbaga, J., Hoff, P. M., & Chammas, R. J. (2023) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2023.12.001
Big Data and Colorectal Cancer: the Revolution will be Personalised
Williams, C. J. M., & Seligmann, J. F. (2024) · Clinical Oncology · doi:10.1016/j.clon.2024.01.010
Guo, Z., He, L., Wang, W., Tian, S., & Lin, R. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4767642
Chiang, S.-W., Huang, Y.-L., Chiang, F., & Chen, M. (2024) · Research Square · doi:10.21203/rs.3.rs-3949891/v1
Metadata
- Authors
- Venook, A. P., Niedzwiecki, D., Lenz, H.-J., Innocenti, F., Fruth, B., Meyerhardt, J. A., Schrag, D., Greene, C., O'Neil, B. H., Atkins, J. N., Berry, S., Polite, B. N., O'Reilly, E. M., Goldberg, R. M., Hochster, H. S., Schilsky, R. L., Bertagnolli, M. M., El-Khoueiry, A. B., Watson, P., Benson, A. B., Mulkerin, D. L., Mayer, R. J., & Blanke, C.
- Affiliations
- University of California, San Francisco (US)
- Duke University (US)
- University of Southern California (US)
- University of North Carolina at Chapel Hill (US)
- Mayo Clinic (US)
- Dana-Farber/Partners CancerCare, Boston, Massachusetts
- Indiana University, Simon Cancer Center, Indianapolis
- Southeastern Medical Oncology Center (US)
- Sunnybrook Health Science Centre (CA)
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois
- Memorial Sloan Kettering Cancer Center (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut
- American Society of Clinical Oncology (US)
- Brigham and Women's Hospital (US)
- Kinston Medical Specialists (US)
- Northwestern University (US)
- University of Wisconsin–Madison (US)
- Oregon Health & Science University (US)
- ORCID
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2017-06-20
- Volume
- 317
- Issue
- 23
- Pages
- 2392
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC5545896
- OpenAlex
- W2712978371
- Cited by
- 898
- References
- 24
- Citations by year
- 2026: 66 · 2025: 76 · 2024: 87 · 2023: 104 · 2022: 118 · 2021: 118 · 2020: 122 · 2019: 107 · 2018: 82 · 2017: 16
- FWCI
- 39.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR001863)
- National Cancer Institute (U10CA180882, K05CA169384, U10CA180820, U10CA180791, U10CA180888, U10CA180836, U10CA180790, U10CA180830, U10CA180795, U10CA180850, R01CA149222, U10CA180838, U10CA180867, U10CA180821, U10CA180799)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Keywords
- metastatic colorectal cancer, KRAS wild-type, cetuximab, bevacizumab, first-line chemotherapy, mFOLFOX6, FOLFIRI, oxaliplatin, irinotecan, monoclonal antibodies, overall survival, progression-free survival, anti-EGFR therapy, anti-VEGF therapy, community oncology
- MeSH terms
- Bevacizumab, Cetuximab, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Canada, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Organoplatinum Compounds, Genes, ras, United States, Colorectal Neoplasms, Treatment Outcome, Disease-Free Survival, Angiogenesis Inhibitors, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
